Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients
Clinical trial NCT00784836 · TERMINATED
Trial details
- NCT number
- NCT00784836
- Sponsor
- Biogen
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2008-10-01
- Primary completion
- 2009-02-01
- Enrollment
- 3
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.